Recent Updates
Recently added Catalysts

ALZN002

Phase 1/2

Alzheimer Disease | Biologics | Neurology |Alzamend Neuro, Inc.|Trials Updated: Sep 30, 2026

ALZN002 target and mechanism

Molecular targetamyloid-beta
Target classProtein
ModalityBiologics

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

ALZN002 clinical trials

ALZN002 · 1 trial · 1 indication

Phase 1/2 1
NCT05834296Study in Subjects With Mild-to-Moderate Alzheimer's DementiaAlzheimer Disease
ACTIVE NOT_RECRUITING30 Analytics
PHASE1/PHASE2ACTIVE NOT_RECRUITING
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Alzheimer DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

TEAEs
Through study completion, up to 33 months

Frequency and severity of TEAEs

Secondary Endpoints

SAEs
Through study completion, up to 33 months
Study Completion
Through study completion, up to 33 months
Number of Participants with changes from baseline in safety laboratory values.
Through study completion, up to 33 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ActiveEXPERIMENTALALZN002 (autologous DCs pulsed with E22W mutant peptide).
PlaceboPLACEBO_COMPARATORSaline ID and IV administrations.

Interventions

NameTypeDescription
ALZN002 (autologous DCs pulsed with E22W mutant peptide).BIOLOGICALThe cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.
PlaceboDRUGSaline
Unlock Study Design Details

Eligibility Criteria

Age Range60 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: Potential study subjects must satisfy the following criteria to be randomized in the study: 1. Age ≥60 and ≤85 years with no restrictions on gender, race, or ethnicity. 2. Able and willing to give informed consent and adhere to study requirements, including testing for cognitiv...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 30, 2026NCT05834296Record updated: Sep 2, 2025 → Sep 30, 2026

Frequently asked questions about ALZN002

What is ALZN002 used for?

ALZN002 is being developed for the treatment of Alzheimer disease. It is an investigational therapy studied in adults with mild-to-moderate Alzheimer's dementia. It has not been approved for any use and remains in clinical development.

What does ALZN002 target?

ALZN002 targets amyloid-beta, a protein that accumulates in the brain in Alzheimer disease. The therapy is described as autologous dendritic cells pulsed with an E22W mutant peptide, a cell-based approach directed at the amyloid-beta target.

Who is developing ALZN002?

ALZN002 is being developed by Alzamend Neuro, Inc., which trades under the ticker ALZN. The company is the sponsor of the clinical program evaluating the therapy in Alzheimer disease.

What phase is ALZN002 in?

ALZN002 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The program includes one active trial that is currently not recruiting participants.

What clinical trial is ALZN002 in?

ALZN002 is being evaluated in the Phase 1 trial NCT05834296, titled Study in Subjects With Mild-to-Moderate Alzheimer's Dementia. The trial is active but not recruiting, is placebo-controlled and double-blind, and is expected to enroll 30 participants in the United States.